Postnatal glucocorticoid therapy for prevention of bronchopulmonary dysplasia: Routes of administration compared

Seminars in Neonatology

Volumn 6, Issue 4, 2001, Pages 343-350

  Cole, Cynthia H ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchopulmonary dysplasia (BPD); Dexamethasone; Inhaled glucocorticoid therapy; Premature infants; Preterm infants; Systemic glucocorticoid therapy

Indexed keywords

BECLOMETASONE; BUDESONIDE; DEXAMETHASONE; FLUORINATED HYDROCARBON; GLUCOCORTICOID;

CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; INCIDENCE; LUNG DYSPLASIA; NEWBORN; NEWBORN MORTALITY; PERINATAL DRUG EXPOSURE; PROPHYLAXIS; REVIEW; SIDE EFFECT; STEROID THERAPY;

EID: 0035740362     PISSN: 10842756     EISSN: None     Source Type: Journal    
DOI: 10.1053/siny.2001.0069     Document Type: Article

References (54)

1. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease
2. The new BPD: An arrest in lung development
3. Pathology of lung disease of early infancy
4. Mechanisms initiating lung injury in the preterm
5. The role of inflammation in the pathogenesis of bronchoplumonary dysplasia
6. Inflammatory mediators in neonatal CLD
7. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops
8. Strategies for prevention of neonatal chronic lung disease
9. Efficacy and safety of inhaled corticosteroids
10. Transcriptional potencies of inhaled glucocorticoids
11. Therapeutic implications of non-genomic glucocorticoid activity
12. Post-natal glucocorticoids in very preterm infants: 'The good, the bad, and the ugly'?
13. Subtle shifts in the ratio between pro- and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate
14. Postnatal steroids: Short-term gain, long-term pain?
15. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants
16. Methylprednisolone, an alternative to dexamethasone in very premature infants at risk for chronic lung disease
17. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants (protocol)
18. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants
19. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants
20. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants
21. Postnatal corticosteroids in preterm infants: Systematic review of effects on mortality and motor function
22. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator ventilator dependency in very low birthweight infants
23. Dexamethasone in neonatal chronic lung disease: Pulmonary effects and intracranial complications
24. Randomized placebo-controlled trial of a 42 day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: Outcome of study participants at 1-year adjusted age
25. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease
26. Meta-analysis of dexamethasone therapy started in the first 15 days of life for prevention of chronic lung disease in premature infants
27. Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia
28. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia
29. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: A randomised trial
30. Early postnatal dexamethasone therapy for the prevention of chronic lung disease
31. Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants
32. Early postnatal dexamethasone therapy is associated with increased incidence of cerebral palsy
33. Early postnatal dexamethasone therapy for prevention of BPD in preterm infants with RDS: A two-year follow-up study
34. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia
35. Inhaled glucocorticoid therapy in infants at risk for neonatal chronic lung disease
36. Inhaled steroids for neonatal chronic lung disease
37. Early Administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates
38. Controlled trial of beclomethasone dipropionate by nebulization in oxygen- and ventilator-dependent infants
39. Effectiveness of budesonide aerosol in ventilator-dependent preterm babies: A preliminary report
40. Ranodomised trial of inhaled steroids in preterm infants with respiratory symptoms at follow-up
41. Early inhaled glucocorticoid therapy for prevention of bronchopulmonary dysplasia
42. Inhaled budesonide in ventilator-dependent preterm infants: A randomized, double-blind pilot study
43. Randomized controlled study of early use of inhaled corticosteroid in preterm infants with respiratory distress syndrome
44. Inhaled salbutamol and beclomethasone for preventing bronchopulmonary dysplasia: A randomised double-blind study
45. Effect of beclomethasone therapy on tracheal aspirate interleukin-8 and interleukin-1 receptor antagonist in preterm ventilated infants at risk for bronchopulmonary dysplasia (BPD)
46. Effect of early glucocorticoid therapy on tracheobronchial lesions in mechanically ventilated preterm infants
47. Adrenal function in premature infants during inhaled beclomethasone therapy
48. Pituitary-adrenal suppression in preterm, very low birth weight infants after inhaled fluticasone propionate treatment
49. Inhaled versus systemic steroids in chronic oxygen dependency of preterm infants
50. Effects of inhaled beclomethasone compared to systemic dexamethasone on lung inflammation in preterm infants at risk of chronic lung disease
51. A multi-center, randomized, open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: A comparison of early and late treatment of dexamethasone and inhaled budesonide
52. Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity
53. The use of aerosolized medicines in neonates